Compare NATL & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NATL | CDNA |
|---|---|---|
| Founded | 2023 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.3B |
| IPO Year | 2023 | 2007 |
| Metric | NATL | CDNA |
|---|---|---|
| Price | $48.09 | $78.51 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 8 |
| Target Price | $50.20 | ★ $94.43 |
| AVG Volume (30 Days) | 714.3K | ★ 1.3M |
| Earning Date | 11-04-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 2.42 | ★ 2.45 |
| Revenue | ★ $4,354,000,000.00 | $48,324,000.00 |
| Revenue This Year | $0.96 | $38.18 |
| Revenue Next Year | $4.77 | $8.98 |
| P/E Ratio | ★ $19.93 | $32.57 |
| Revenue Growth | N/A | ★ 18.93 |
| 52 Week Low | $33.31 | $15.15 |
| 52 Week High | $48.60 | $90.87 |
| Indicator | NATL | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 64.14 | 55.69 |
| Support Level | $44.91 | $17.15 |
| Resistance Level | $48.19 | $90.87 |
| Average True Range (ATR) | 0.93 | 5.25 |
| MACD | 0.17 | -0.62 |
| Stochastic Oscillator | 85.10 | 44.81 |
NCR Atleos Corp is a financial technology company providing self-directed banking solutions to a customer base including financial institutions, merchants, manufacturers, retailers, and consumers. Self-directed banking is a rapidly growing, secular trend that allows banking customers to transact seamlessly between various channels, all for the same transaction. Their comprehensive solutions enable the acceleration of self-directed banking through ATM and interactive teller machine (ITM) technology, including software, services, hardware, and its proprietary Allpoint network. Atleos manages its operations in the following segments: Self-Service Banking, which generates maximum revenue, Network, and Telecommunications and Technology. Geographically, it derives maximum revenue from the U.S.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.